$3.78
1.89%
Nasdaq, Fri, Sep 25 2026.
ISIN
US19207A1088
Symbol
COEP

Coeptis Therapeutics Stock price

$3.78
-0.32 7.80% 1M
-7.41 66.22% 6M
-10.47 73.47% YTD
-12.88 77.31% 1Y
-15.21 80.09% 3Y
-195.02 98.10% 5Y
-194.22 98.09% 10Y
-194.22 98.09% 20Y
Nasdaq, Closing price Fri, Sep 25 2026
+0.07 1.89%
ISIN
US19207A1088
Symbol
COEP
Industry

Is Coeptis Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
53.5%
Return on Equity
-493.0%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
-
FCF per Share
-
Short interest
8.0%
Employees
5
Rev per Employee
$0.0

Coeptis Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Coeptis Therapeutics forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Coeptis Therapeutics forecast:

Hold
50%
Sell
50%

Financial data from Coeptis Therapeutics

Dec '23
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 15 15
-
-
- Research and Development Expense 6.40 6.40
-
-
-20 -20
-
-
- Depreciation and Amortization 1 1
-
-
EBIT (Operating Income) EBIT -21 -21
67% 67%
-
Net Profit -21 -21
69% 69%
-

In millions USD.

Don't miss a Thing! We will send you all news about Coeptis Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Coeptis Therapeutics Stock News

Neutral
PRNewsWire
●
5 months ago
~ Shares to Commence Trading on the Nasdaq Global Market Under Ticker Symbol "ZSQR" Monday April 27, 2026 ~ FORT LAUDERDALE, Fla, April 24, 2026 /PRNewswire/ -- Z Squared, Inc. (Nasdaq: ZSQR) ("Z Squared" or the "Company"), a vertically integrated computing infrastructure company, today announced the completion of its business combination with Coeptis Therapeutics Holdings, Inc. ("Coeptis"). In...
Neutral
GlobeNewsWire
●
6 months ago
~ Approval Marks Satisfaction of Key Closing Condition in Pending Merger ~ WEXFORD, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or the “Company”), a next-gen technology and biopharmaceutical company, today announced that Nasdaq has approved, subject to customary conditions and the closing of the proposed merger, the listing of the post-m...

Company Profile

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company. It develops innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.

Head office United States
CEO Mr. Mehalick
Employees 5
Founded 2017
Website coeptistx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today